title: [Treatment of Patients with ALK-positive Non-small Cell Lung Cancer  and Brain Metastases].
abstract: BACKGROUND
  Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is an important subtype of lung cancer. The standard modality of ALK-positive NSCLC with brain metastases remains uncertain.
  
  
  METHODS
  We collected data on clinical characteristics and treatment of patients with ALK-positive NSCLC and brain metastases between March 2013 and March 2016 and retrospectively analyzed patient outcomes.
  
  
  RESULTS
  In 84 ALK-positive patients with advanced NSCLC, 22 (26.2%) had brain metastases during the initial diagnosis of lung cancer, among which 3 patients with EGFR mutation were excluded, and 19 patients were analyzed. Median intracranial progression-free survival (PFS) was 12.0 months. PFS for patients who received first-line local brain therapy (P=0.021) and crizotinib therapy (P=0.030) was superior to PFS for patients without such therapies. PFS for patients who received first-line crizotinib combined with local brain therapy was 27.0 months and only 4.2 months for those who received crizotinib alone.
  
  
  CONCLUSIONS
  First-line crizotinib therapy combined with local brain treatment can improve intracranial PFS for ALK-positive NSCLC with brain metastases. This finding should be confirmed further through multicenter, prospective clinical trials with large sample size.
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Jialin
authors: J
authors: Lv
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Quan
authors: Q
authors: Zhang
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Na
authors: N
authors: Qin
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Xinjie
authors: X
authors: Yang
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Xinyong
authors: X
authors: Zhang
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Yuhua
authors: Y
authors: Wu
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Xi
authors: X
authors: Li
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Hui
authors: H
authors: Zhang
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Jinghui
authors: J
authors: Wang
authors: Department of Medical Oncology, Beijing Chest Hospital, Capital Medicine University, Beijing Tuberculosis and Thoracic Tumor  Research Institute, Beijing 101149, China.
authors: Shucai
authors: S
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology* / Q000473:pathology*; D000077547:Crizotinib; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases